Imaging and Tissue Biomarkers in Patients with Newly Diagnosed GBM

新诊断 GBM 患者的影像学和组织生物标志物

• 批准号: 7383588
• 负责人: SARAH J. NELSON
• 金额: $ 39.85万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-28 至 2013-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7383588
• 关键词: Adjuvant; Anatomy; Angiogenesis Inhibitors; Apoptosis; Area; Arts; Behavior; Biological; Biological Markers; Biological Models; Biopsy Specimen; Blood Vessels; Blood Volume; Caring; Cell Density; Cerebrum; Characteristics; Choline; Clinical; Clinical Management; Clinical Trials; Data; Decision Making; Diffusion; Diffusion weighted imaging; Disease; Evaluation; Excision; Exhibits; Extracellular Matrix; Freezing; Functional Imaging; Future; Glioblastoma; Growth; Height; Heterogeneity; Hypoxia; Image; Image Guided Biopsy; Imaging Techniques; Invaded; Invasive; Knowledge; Lesion; Link; Location; Magic; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Measures; Metabolic; Metabolism; Methods; Microscopic; Modality; Molecular; Morphology; NMR Spectroscopy; New Agents; Newly Diagnosed; Operative Surgical Procedures; Outcome; Paraffin Embedding; Patient Care; Patient Selection; Patients; Pattern; Perfusion; Phase II Clinical Trials; Physiological; Property; Radiation; Radiation therapy; Recruitment Activity; Relative (related person); Residual Tumors; Residual state; Resolution; Sampling; Therapeutic; Thinking; Time; Tissue Sample; Tissues; Tumor Angiogenesis; Tumor Burden; Tumor-Associated Process; Uncertainty; Week; Weight; base; chemotherapy; cytotoxic; density; design; follow-up; improved; in vivo; interest; magnetic resonance spectroscopic imaging; neoplastic cell; neuron loss; prognostic; response; temozolomide; tumor

DESCRIPTION (provided by applicant): The objective of this project is to integrate metabolic and physiologic MR imaging data into the clinical management of patients with newly diagnosed glioblastoma multiforme (GBM) who are being treated with combined radiation, chemo and antiangiogenic therapy. Our current studies have provided strong evidence that Magnetic Resonance Spectroscopic Imaging (MRSI), Perfusion Weighted imaging (PWI) and Diffusion Weighted Imaging (DWI) produce information concerning the biological behavior of such lesions that is likely to be valuable for clinical decision making. We propose to explore the impact of these imaging methods with respect to quantifying changes in imaging parameters and assessing therapeutic response in patients treated with concurrent Enzastaurin, Temozolomide and Radiation Therapy (ETRT), a therapeutic strategy that combines cytotoxic and antiangiogenic approaches. The first area that is of interest is to validate the biological interpretation of selected imaging variables presumed to be representative surrogates for tumor extent, heterogeneity, and therapeutic responsiveness, as well as prognostic significance with respect to survival. The second area of interest is in evaluating imaging characteristics prior to ETRT and their short and longer term changes that occur as a result of ETRT in order to quantify and assess treatment response. Previous studies have not utilized state of the art metabolic and physiologic imaging methods to select patients, to identify microscopic disease and heterogeneity or to evaluate response to therapy. We believe that it is critical to determine whether this approach is feasible and to obtain evidence that would help in deciding how to best integrate such information into future clinical trials. Specific Aim 1 will provide direct correlation between specific in vivo imaging and tissue characteristics by immunohistochemical and ex vivo NMR spectroscopy of image guided surgical samples from patients with newly diagnosed GBM. This will establish the link between in vivo and ex vivo MR parameters and biological behavior as defined by molecular morphology. Specific Aim 2 will analyze the characteristics of GBM in patients who are participating in an institutional Phase II clinical trial of ETRT. It will examine the relationship between pre-ETRT MR parameters and subsequent imaging changes at multiple time points up to 6 months after completion of RT. While the focus of this proposal is on one specific clinical trial, the knowledge that will be gained has broad implications for selecting and designing many other types of antiangiogenic and molecularly targeted therapies and is likely to enhance the non-invasive imaging based interpretation of treatment response, change the definition of tumor burden in patients with GBM as well as improve patient selection for future clinical trials.

描述（由申请人提供）：本项目的目的是将代谢和生理MR成像数据整合到正在接受联合放疗、化疗和抗血管生成治疗的新诊断多形性胶质母细胞瘤（GBM）患者的临床管理中。我们目前的研究提供了强有力的证据，磁共振波谱成像（MRSI），灌注加权成像（PWI）和扩散加权成像（DWI）产生的信息，这些病变的生物学行为，可能是有价值的临床决策。我们建议探索这些成像方法在量化成像参数变化和评估同时接受恩扎妥林、替莫唑胺和放射治疗（ETRT）的患者的治疗反应方面的影响，ETRT是一种结合细胞毒性和抗血管生成方法的治疗策略。感兴趣的第一个领域是验证选定的成像变量的生物学解释，这些变量被认为是肿瘤范围、异质性和治疗反应性的代表性替代物，以及与生存率相关的预后意义。第二个感兴趣的领域是评价ETRT之前的成像特征及其因ETRT而发生的短期和长期变化，以量化和评估治疗反应。以前的研究没有利用最先进的代谢和生理成像方法来选择患者，以确定微观疾病和异质性或评价对治疗的反应。我们认为，关键是要确定这种方法是否可行，并获得证据，这将有助于决定如何最好地将这些信息整合到未来的临床试验。 特异性目标1将通过免疫组织化学和来自新诊断GBM患者的图像引导手术样本的离体NMR光谱提供特异性体内成像与组织特征之间的直接相关性。这将建立体内和离体MR参数与分子形态学定义的生物学行为之间的联系。具体目标2将分析参与ETRT机构II期临床试验的患者的GBM特征。它将检查ETRT前MR参数与RT完成后6个月内多个时间点的后续成像变化之间的关系。虽然该提案的重点是一项特定的临床试验，将获得的知识对于选择和设计许多其他类型的抗血管生成和分子靶向疗法具有广泛的意义，并且可能增强非血管生成和分子靶向疗法。基于侵入性成像对治疗反应的解释，改变了GBM患者肿瘤负荷的定义，并改善了未来临床试验的患者选择。